154 related articles for article (PubMed ID: 22484368)
1. Pricing of drugs with heterogeneous health insurance coverage.
Ferrara I; Missios P
J Health Econ; 2012 Mar; 31(2):440-56. PubMed ID: 22484368
[TBL] [Abstract][Full Text] [Related]
2. Competition between brand-name and generics--analysis on pricing of brand-name pharmaceutical.
Kong Y
Health Econ; 2009 May; 18(5):591-606. PubMed ID: 18816580
[TBL] [Abstract][Full Text] [Related]
3. The effect of generic competition on the price of brand-name drugs.
Lexchin J
Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
[TBL] [Abstract][Full Text] [Related]
4. Reference pricing of pharmaceuticals.
Brekke KR; Königbauer I; Straume OR
J Health Econ; 2007 May; 26(3):613-42. PubMed ID: 17188769
[TBL] [Abstract][Full Text] [Related]
5. The association of insurance type with costs of dispensed drugs.
Mott DA; Kreling DH
Inquiry; 1998; 35(1):23-35. PubMed ID: 9597015
[TBL] [Abstract][Full Text] [Related]
6. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
Goedken AM; Urmie JM; Farris KB; Doucette WR
Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
[TBL] [Abstract][Full Text] [Related]
7. Do pharmaceutical prices respond to potential patient out-of-pocket expenses?
Pavenik N
Rand J Econ; 2002; 33(3):469-87. PubMed ID: 12585303
[TBL] [Abstract][Full Text] [Related]
8. Limited options to manage specialty drug spending.
Tu HT; Samuel DR
Res Brief; 2012 Apr; (22):1-13. PubMed ID: 23155549
[TBL] [Abstract][Full Text] [Related]
9. OSTEOPOROSIS DRUGS MARKETED IN THE UNITED STATES: GENERIC COMPETITION, PRICING STRUCTURE, AND DISPERSION AMONG PAYERS.
Balkhi B; Seoane-Vazquez E; Rodriguez-Monguio R
Int J Technol Assess Health Care; 2016 Jan; 32(6):385-392. PubMed ID: 28065194
[TBL] [Abstract][Full Text] [Related]
10. Impacts of regulated competition on pricing in Chinese pharmaceutical market under urban employee basic medical insurance.
Zhao M; Wu J
Expert Rev Pharmacoecon Outcomes Res; 2017 Jun; 17(3):311-320. PubMed ID: 27762144
[TBL] [Abstract][Full Text] [Related]
11. Impact of the Minimum Pricing Policy and introduction of brand (generic) substitution into the Pharmaceutical Benefits Scheme in Australia.
McManus P; Birkett DJ; Dudley J; Stevens A
Pharmacoepidemiol Drug Saf; 2001; 10(4):295-300. PubMed ID: 11760489
[TBL] [Abstract][Full Text] [Related]
12. Effects of innovation and insurance coverage on price elasticity of demand for prescription drugs: some empirical lessons in pharmacoeconomics.
Mendoza RL
J Med Econ; 2020 Sep; 23(9):915-922. PubMed ID: 32432950
[TBL] [Abstract][Full Text] [Related]
13. Potential savings from increased use of generic drugs in the elderly: what the experience of Medicaid and other insurance programs means for a Medicare drug benefit.
Fischer MA; Avorn J
Pharmacoepidemiol Drug Saf; 2004 Apr; 13(4):207-14. PubMed ID: 15255087
[TBL] [Abstract][Full Text] [Related]
14. Reference pricing with endogenous generic entry.
Brekke KR; Canta C; Straume OR
J Health Econ; 2016 Dec; 50():312-329. PubMed ID: 27350294
[TBL] [Abstract][Full Text] [Related]
15. Product-line extensions and pricing strategies of brand-name drugs facing patent expiration.
Hong SH; Shepherd MD; Scoones D; Wan TT
J Manag Care Pharm; 2005; 11(9):746-54. PubMed ID: 16300418
[TBL] [Abstract][Full Text] [Related]
16. Effect of generic-only drug benefits on seniors' medication use and financial burden.
Tseng CW; Brook RH; Keeler E; Steers WN; Waitzfelder BE; Mangione CM
Am J Manag Care; 2006 Sep; 12(9):525-32. PubMed ID: 16961441
[TBL] [Abstract][Full Text] [Related]
17. Competition and the Reference Pricing Scheme for pharmaceuticals.
Ghislandi S
J Health Econ; 2011 Dec; 30(6):1137-49. PubMed ID: 21937137
[TBL] [Abstract][Full Text] [Related]
18. Price regulation and generic competition in the pharmaceutical market.
Dalen DM; Strøm S; Haabeth T
Eur J Health Econ; 2006 Sep; 7(3):208-14. PubMed ID: 16841230
[TBL] [Abstract][Full Text] [Related]
19. [The effect of generic price competition on drug consumption and health insurance pharmaceutical expenditures in Hungary].
Répásy B; Endrei D; Zemplényi A; Agoston I; Hornyák L; Nagy Z; Csákvári T; Vajda R; Boncz Imre
Acta Pharm Hung; 2015; 85(3):83-8. PubMed ID: 26642646
[TBL] [Abstract][Full Text] [Related]
20. Does generic entry lower the prices paid for pharmaceuticals in Australia? A comparison before and after the introduction of the mandatory price-reduction policy.
Spinks J; Chen G; Donovan L
Aust Health Rev; 2013 Nov; 37(5):675-81. PubMed ID: 24160374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
